We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Blood Test Taken After Miscarriage Can Predict Future Risk of Pregnancy Loss

By LabMedica International staff writers
Posted on 18 May 2023

Approximately 10% of women experience pregnancy loss, a percentage that is higher in regions where pregnancies frequently occur later in a woman's reproductive years. More...

Various factors contribute to pregnancy loss, including hormonal imbalances, endocrine disorders, clotting issues, or lifestyle-related factors. Despite the fact that one in four pregnancies results in a miscarriage, little has been done to investigate the underlying causes, with the primary focus being on the process of uterus evacuation post-miscarriage. Now, a new study has found that a post-miscarriage blood test as early as the fifth week of pregnancy could shed light on the cause and, in some instances, guide preventative treatment strategies. These findings could potentially help prevent 5% of the annual 30 million miscarriages worldwide.

In the study, a team of researchers at Hvidovre Hospital (Hvidovre, Denmark) demonstrated that a blood sample taken from the mother shortly after a miscarriage that occurred as early as the fifth week of pregnancy can identify whether there was a chromosomal abnormality in the fetus. Such tests are typically only administered after a woman has experienced multiple miscarriages and if they occurred past the tenth week of pregnancy.

This blood test can be immediately dispatched to the hospital laboratory. Here, the fetal DNA is isolated, sequenced, and analyzed for chromosomal abnormalities, which are present in approximately 50 to 60% of miscarriages. This analysis allows doctors to identify the severity of these abnormalities and estimate the risk of future miscarriages. If no abnormalities are detected, doctors can then initiate an in-depth investigation for other causes. If a cause is identified, medical professionals can assess the risks and formulate an appropriate treatment plan.

Related Links:
Hvidovre Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Proscia advances Agilent’s efforts to expand its pathology portfolio and strengthens its competitive position in a rapidly growing market.

Agilent Acquisition of Proscia to Advance AI-Enabled Digital Pathology Workflows

Agilent Technologies Inc. has entered into a definitive agreement to acquire Proscia, a provider of digital pathology software for clinical and life-sciences customers. The all-cash transaction is valued... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.